Navigation Links
FASgen, Inc. Announces Research and License Agreement With Centocor, Inc.
Date:1/6/2009

BALTIMORE, Jan. 6 /PRNewswire/ -- FASgen, Inc. is pleased to announce that it has entered into a research and license agreement with Centocor, Inc. This agreement will give Centocor, Inc. and its Ortho Biotech Oncology Research and Development division affiliates the opportunity to discover and develop novel small molecule inhibitors of the fatty acid biosynthesis pathway via selective inhibition of Fatty Acid Synthase (FAS) for use in Oncology. The FASgen researchers have extensive experience studying the over-expression of FAS, an enzyme over-expressed in virtually all solid tumors. The inhibition of FAS causes tumor cell apoptosis and holds promise for new therapeutic treatments for cancer.

The economic terms of the research collaboration were not disclosed.

About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished Johns Hopkins researchers to create new therapeutic products based on the selective inhibition of fatty acid biosynthesis. The Company has the exclusive license from Johns Hopkins to more than 15 years of research in the field, which research continues under a sponsored research agreement with the University. The Company has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer. Additional compounds have the potential of specific therapeutics for obesity and related metabolic disorders including diabetes, dysplipidemia fatty liver disease and non-alcoholic steatohepatitis. A final group of compounds have the potential of specific therapeutics against TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that affect one third of the world's population. For more information, visit FASgen's website at www.fasgen.com.


'/>"/>
SOURCE FASgen, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. B2B Marketing Pro Toby Younis Announces Free Webcast on "BuzzMaking"
2. Alfacell Announces Receipt of NASDAQ Panel Decision
3. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
4. Go Ask Alice ... Nationally Recognized Life Coach & Psychotherapist, Alice Donavin, LCSW Announces the Implementation of Office/House Calls to her Newly Launched Philadelphia Practice
5. Mobile Massage Team Announces Eleven New Therapist Members in the Northeast U.S. Region
6. Misonix Announces New HIFU Distribution Agreement for Italy
7. Four Rivers Software Systems Announces Integration with ePartsFinder from PartsSource
8. Summa Health Network Announces Contract with MDdatacor to Support Multi-Insurer Health Care Quality Initiative; Initiative to Use Clinical Data to Supplement Claims Data and Enhance Outcomes
9. Dialysis Corporation of America Announces Acquisition of Maryland Dialysis Center
10. SXC Health Solutions announces contract with PharMerica
11. MedCath Corporation Announces Completion of Sale of Equity Interest in Joint Venture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates ... joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient ... to add this excellent dermatology practice to our group’s medical services,” explains NCMA ...
(Date:1/20/2017)... ... , ... Spectrum Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, ... on wheels, it can be wheeled out of the way and stored when not in ... "We have transformed the feedback from customers into specific enhancements and created a new product ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... Doctor ... announced it attended the January ECRM trade show to continue the marketing and distribution ... vitamin C supplement, known for providing 400 percent better absorption than traditional vitamin C ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... highest level of nutritional and bodybuilding supplements, announced it attended the January ECRM trade ... a respected bodybuilder and nutritional scientist who was determined to create a line of ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Mary Magdalene: Grace is Greater than Sin”: ... who witnessed Jesus Christ firsthand. “Mary Magdalene: Grace is Greater than Sin” is the ... an educator interacting with countless women who had little knowledge of the female characters ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Pharmaceuticals Inc. (NASDAQ: SGYP ), Novo Nordisk A/S ... SCMP ), and Pernix Therapeutics Holdings Inc. (NASDAQ: ... which fell on Thursday, January 19 th , 2017, finishing ... NYSE Health Care Index dropped over 0.7%, while shares of ...
(Date:1/20/2017)... Avillion LLP, a co-developer and financier of late-stage pharmaceutical product candidates, ... Chief Medical Officer. Dr Weinberg will be based in ... ... 17 years as a pharmaceutical and biotech executive with experience ranging ... of his career, he has interfaced with the US Food & ...
(Date:1/19/2017)... 19, 2017 The U.S. Food and Drug Administration ... Constipation (CIC) in adult patients. "No one ... said Julie Beitz , M.D., director of the Office ... Evaluation and Research. "With the availability of new therapies, patients ... their condition." ...
Breaking Medicine Technology: